irinotecan has been researched along with Lymphoma, Large B-Cell, Diffuse in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (12.50) | 18.2507 |
2000's | 6 (75.00) | 29.6817 |
2010's | 1 (12.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kadowaki, M; Kohno, K; Kondo, S; Kubota, A; Okamura, S; Takase, K; Takeshita, M; Tanimoto, K; Yamasaki, S | 1 |
Barker, JN; Gupta, NK; Noy, A; Young, JW | 1 |
Kirschbaum, M | 1 |
Fukushima, T; Hirose, Y; Karasawa, H; Kawabata, H; Kawanami, T; Masaki, Y; Ogawa, N; Sawaki, T; Shimoyama, K; Sugai, S; Umehara, H; Wano, Y | 1 |
Bessho, M; Higashihara, M; Kohuri, M; Niitsu, N | 1 |
Kang, HJ; Kim, BS; Kim, WS; Park, YH; Ryoo, BY; Suh, C; Yuh, YJ | 1 |
Amaya, N; Tsutani, H; Ueda, T; Yamauchi, T; Yoshida, A; Yoshio, N | 1 |
Asai, J; Fujimoto, T; Miyo, T; Nagashima, G; Suzuki, R | 1 |
2 trial(s) available for irinotecan and Lymphoma, Large B-Cell, Diffuse
Article | Year |
---|---|
Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Mitoxantrone; Natriuretic Peptide, Brain; NM23 Nucleoside Diphosphate Kinases; Nucleoside-Diphosphate Kinase; Prognosis; Recurrence; Rituximab; Survival Analysis; Survival Rate; Treatment Outcome; Troponin T | 2006 |
Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prednisone; Prospective Studies; Rituximab; Salvage Therapy; Vincristine | 2008 |
6 other study(ies) available for irinotecan and Lymphoma, Large B-Cell, Diffuse
Article | Year |
---|---|
UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Dexamethasone; Etoposide; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Recurrence; Treatment Outcome | 2015 |
Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Cyclosporine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Remission Induction; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2009 |
Comeback for the camptothecins?
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Remission Induction; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2009 |
[Successful salvage therapy of continuous low-dose irinotecan for a patient with relapsed and refractory diffuse large B-cell lymphoma].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Remission Induction; Salvage Therapy; Treatment Outcome | 2005 |
Successful salvage treatment with irinotecan (CPT-11) of recurrent malignant lymphoma in an aged patient; and CPT-11 pharmacokinetics.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Recurrence; Salvage Therapy | 1999 |
[Irinotecan (topoisomerase-I inhibitor) for the treatment of recurrent primary intracranial malignant lymphoma].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cerebellar Neoplasms; Cranial Irradiation; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local | 2000 |